This is a non-core endpoint: only basic statistics are computed.
Carcinoma in situ of rectosigmoid junction
CD2_INSITU_RECTOSIGMOID_EXALLC
No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
|
1. Apply sex-specific ruleNone |
- |
2. Check conditionsNone |
|
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
- |
4. Check minimum number of eventsNone |
- |
5. Include endpointsNone |
- |
6. Filter based on genotype QC (FinnGen only)None |
- |
Control definitions (FinnGen only)
- Control exclude
- C3_CANCER, C3_CANCER_WIDE
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- D01
- Name in latin
- Carcinoma in situ junctionis rectosigmoideae
Similar endpoints
↥List of similar endpoints to
Carcinoma in situ of rectosigmoid junction
based on the number of shared cases.
Similar with more cases:
- Carcinoma in situ of rectosigmoid junction
- Carcinoma in situ of other and unspecified digestive organs
- Carcinoma in situ of other and unspecified digestive organs
- In situ neoplasms
- In situ neoplasms
Similar with less cases:
Case counts by codes
↥FinnGen case counts by registry codes:
No upset plot: script not run.
No upset table: script not run.
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 10 | 6 | - |
| Unadjusted period prevalence (%) | 0.00 | 0.00 | - |
| Median age at first event (years) | 63.98 | 59.64 | - |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
No data available
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
unit
cases
controls
-log10(p)
N cases
N controls
(3023368) Bacteria identified in Blood by Culture
5
15
5.54
1.77
4.4
3.6
—
—
—
0
0
(3012516) Albumin [Mass/volume] in Urine
5
19
4.19
1.41
2.8
2.5
mg/l
14.5
16.5
—
5
13
(42870588) Differential panel, method unspecified - Blood
5
19
4.19
1.41
4.0
7.1
—
—
—
0
0
(3029287) Urinalysis microscopic panel [#/volume] - Urine by Automated count
5
20
3.94
1.34
6.0
3.1
—
—
—
0
0
(3015736) pH of Urine
5
32
2.11
0.52
7.8
2.5
—
—
—
0
0
(3035350) Ketones [Presence] in Urine by Test strip
5
37
1.69
0.30
8.0
2.3
—
0.0
—
0
6
(3048773) Triglyceride [Moles/volume] in Serum or Plasma --fasting
5
63
0.59
0.30
3.8
4.0
mmol/l
1.2
1.2
—
5
58
(42868674) Cholesterol in HDL/Cholesterol.total [Molar ratio] in Serum or Plasma
0
13
0.00
0.22
0.0
3.4
—
33.6
—
0
8
(3009261) Glucose [Presence] in Urine by Test strip
5
40
1.49
0.13
8.0
2.4
—
0.0
—
0
6
(3016293) Bicarbonate [Moles/volume] in Serum or Plasma
0
5
0.00
0.00
0.0
8.4
—
25.9
—
0
5
(3007628) Bicarbonate [Moles/volume] standard in Venous blood
0
5
0.00
0.00
0.0
14.2
—
25.4
—
0
5
(3001019) Free T4 and TSH panel - Serum or Plasma
0
5
0.00
0.00
0.0
3.8
—
—
—
0
0
(3002173) Hemoglobin [Mass/volume] in Arterial blood
0
5
0.00
0.00
0.0
13.4
—
109.2
—
0
5
(3005785) Creatine kinase.MB [Mass/volume] in Serum or Plasma
0
5
0.00
0.00
0.0
1.6
—
6.0
—
0
5
(3000991) Gas panel - Venous blood
0
6
0.00
0.00
0.0
22.7
—
—
—
0
0
(3024950) Chlamydia trachomatis DNA [Presence] in Urine by NAA with probe detection
0
9
0.00
0.00
0.0
1.4
—
—
—
0
0
(3045783) Sodium and Potassium panel [Moles/volume] - Serum or Plasma
0
9
0.00
0.00
0.0
5.3
—
—
—
0
0
(40761536) Microorganisms panel - Urine sediment
0
6
0.00
0.00
0.0
4.8
—
—
—
0
0
(3016502) Oxygen saturation in Arterial blood
0
6
0.00
0.00
0.0
11.5
—
93.3
—
0
6
(3020779) Urea [Moles/volume] in Serum or Plasma
0
7
0.00
0.00
0.0
13.0
—
12.2
—
0
7
(3014111) Lactate [Moles/volume] in Serum or Plasma
0
7
0.00
0.00
0.0
11.6
—
1.0
—
0
7
(3019832) Treponema pallidum Ab [Presence] in Serum
0
9
0.00
0.00
0.0
1.3
—
—
—
0
0
(3003510) Neisseria gonorrhoeae DNA [Presence] in Urine by NAA with probe detection
0
7
0.00
0.00
0.0
1.4
—
—
—
0
0
(3026493) Urate [Moles/volume] in Serum or Plasma
0
8
0.00
-0.00
0.0
3.0
—
352.3
—
0
8
(3002109) Cholesterol in LDL/Cholesterol in HDL [Mass Ratio] in Serum or Plasma
0
8
0.00
-0.00
0.0
1.5
—
—
—
0
0
(3019902) Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture
0
8
0.00
-0.00
0.0
2.1
—
—
—
0
0
(21494755) Public health laboratory ask at order entry panel
0
8
0.00
-0.00
0.0
1.4
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: CD2_INSITU_RECTOSIGMOID_EXALLC – Carcinoma in situ of rectosigmoid junction
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).